- Home
- Sign in to Your Customer Portal | Optum Business
- Business Customer Support | Optum Business
- Product Support Portals | Optum Business
- Medical, Hospital and Dental Enrollment Forms | Optum Business
- Payer Lists | Optum Business
- State Payer Sheets | Optum Business
- Change Healthcare Formulary Drug Lists | Optum Business
- Specialty Pharmacy Referral and Enrollment Forms
- Infusion Pharmacy Referral and Enrollment Forms
- RX Professionals Resources and Support
- Dovato (dolutegravir/lamivudine) – Expanded indication
- Livmarli® (maralixibat) – Expanded indication, new strength
- Abecma® (idecabtagene vicleucel) – Expanded indication
- Abrysvo® (respiratory syncytial virus vaccine) – New indication
- ACAM2000™ (smallpox and mpox (vaccinia) vaccine, live) – New indication
- Alecensa® (alectinib) – New indication
- Balversa® (erdafitinib) – Updated indication, accelerated approval converted to full approval
- Besponsa™ (inotuzumab ozogamicin) – Updated indication
- Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – Expanded indication
- Bimzelx® (bimekizumab) – New indications
- Bimzelx® (bimekizumab-bkzx) – New indication
- Braftovi® (encorafenib) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Calquence® (acalabrutinib) – New indication, accelerated approval converted to traditional approval
- Health Care Professionals Portal Terms of Use
- Carvykti® (ciltacabtagene autoleucel) – Expanded indication
- Casgevy™ (exagamglogene autotemcel) – New orphan indication
- Cimzia® (certolizumab pegol) – New indication
- Pfizer/BioNTech, Moderna, and Novavax COVID-19 vaccines (Omicron variant XBB.1.5) – CDC recommends an additional vaccine dose in 65 years and older
- COVID-19 vaccines – ACIP recommends additional 2024-2025 vaccine doses for certain groups
- Dupixent® (dupilumab) – Expanded indication
- Dupixent® (dupilumab) – Expanded indication
- Dupixent® (dupilumab) for COPD – New indication approval
- Enhertu® (fam-trastuzumab deruxtecan-nxki) – New indication
- Enhertu® (trastuzumab deruxtecan) – Expanded indication
- Entyvio® (vedolizumab) – New indication for subcutaneous use
- Fanapt® (iloperidone) – New indication
- Farxiga® (dapagliflozin) – First-time authorized brand alternative
- Fasenra® (benralizumab) – Expanded indication
- Fasenra® (benralizumab) – New indication
- Filspari® (sparsentan) – Updated indication, accelerated approval converted to full approval
- Gammagard Liquid® (immune globulin infusion [human] 10% solution) – New indication
- Gemtesa® (vibegron) – New indication
- Iclusig® (ponatinib) – Expanded indication
- Imcivree® (setmelanotide) – Expanded indication
- Imfinzi® (durvalumab) – New indication
- Invokana® (canagliflozin), Invokamet/Invokamet® XR (canagliflozin/metformin) – Expanded indication
- Ixinity® (coagulation factor IX [recombinant]) – Expanded indication
- Keytruda® (pembrolizumab) – Expanded indication
- Keytruda® (pembrolizumab) – Updated indication, accelerated approval converted to full approval
- Keytruda® (pembrolizumab) – New indication
- Kisqali® (ribociclib) – New indication
- Livmarli® (maralixibat) – New indication
- Lumakras® (sotorasib) plus Vectibix® (panitumumab) – New indication
- Lumryz™ (sodium oxybate) – Expanded indication
- Lutathera® (lutetium Lu 177 dotatate) – Expanded indication
- Mircera® (methoxy polyethylene glycol-epoetin beta) – Expanded indication
- Moderna COVID-19 Vaccine – Expanded emergency use authorization
- Nemluvio® (nemolizumab-ilto) – New indication
- Nexletol® (bempedoic acid), Nexlizet® (bempedoic acid/ezetimibe) – New/expanded indications
- Novavax COVID-19 vaccine, adjuvanted (2024-2025 formula) – Emergency Use Authorization
- Odactra® (Dermatophagoides farinae and Dermatophagoides pteronyssinus) – Expanded indication
- Omvoh® (mirikizumab-mrkz) – New indication
- Onivyde® (irinotecan liposome injection) – New indication
- Opdivo® (nivolumab) – New indication
- Otezla® (apremilast) – Expanded indication
- Ozempic® (semaglutide) – New indication
- Pemgarda™ (pemivibart) – Emergency use authorization approval
- Piqray® (alpelisib) – Expanded indication
- Praluent® (alirocumab) – Expanded indication
- Prevymis® (letermovir) – Expanded indication, new dosage formulation
- Rybrevant® (amivantamab-vmjw) – New indication, accelerated approval converted to full approval
- Rybrevant® (amivantamab-vmjw) – New indication
- Sarclisa® (isatuximab-irfc) – New indication
- Scemblix® (asciminib) – New indication
- Selarsdi™ (ustekinumab-aekn) – New indications and formulation approval
- Soliris® (eculizumab) – Expanded indication
- Spevigo® (spesolimab-sbzo) – Expanded indication
- Spravato® (esketamine) – Expanded indication
- Tagrisso® (osimertinib) – New indication
- Tevimbra® (tislelizumab-jsgr) – New indication
- Tremfya® (guselkumab) – New indication
- Trikafta® (elexacaftor/tezacaftor/ivacaftor; ivacaftor) – Updated label, boxed warning added
- Trodelvy™ (sacituzumab govitecan-hziy) – Indication withdrawal
- Ultomiris® (ravulizumab-cwvz) – New indication
- Veklury® (remdesivir) – Expanded indication
- Vemlidy® (tenofovir alafenamide) – New indication
- Vtama® (tapinarof) – New indication
- Xhance® (fluticasone propionate) – New indication
- Xigduo® XR (dapagliflozin/metformin) – First-time authorized brand alternative
- Xofluza® (baloxavir marboxil) – Expanded indication
- Xolair® (omalizumab) – New indication
- Zepbound® (tirzepatide) – New indication
- Arexvy® (respiratory syncytial virus vaccine) – Expanded indication
- Arixtra® (fondaparinux) – New indication
- Augtyro™ (repotrectinib) – New indication
- Blincyto® (blinatumomab) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Comirnaty® and Spikevax® (KP.2) 2024 – 2025 vaccines – FDA approval and Emergency Use Authorization
- COVID-19 vaccines – FDA makes recommendations for new monovalent vaccine composition for 2024-2025
- COVID-19 vaccines – ACIP makes recommendations for 2024-2025 vaccine administration
- COVID-19 vaccines – VRBPAC makes recommendations for new monovalent vaccine composition
- Epkinly® (epcoritamab-bysp) – New indication
- Fabhalta® (iptacopan) – New indication
- Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication
- Fibryga® (fibrinogen [human]) – New indication
- Firdapse® (amifampridine) – Updated dosing
- Furoscix® (furosemide) – Expanded indication
- Imfinzi® (durvalumab) – New indication
- Imfinzi® (durvalumab) – New indication
- Imfinzi® (durvalumab) – New indication
- Kevzara® (sarilumab) – New indication
- Keytruda® (pembrolizumab) – New indication
- Kisqali® (ribociclib) – Updated indication
- Krazati® (adagrasib) – New indication
- Motpoly XR™ (lacosamide) – New indication
- Nexobrid® (anacaulase-bcdb) – Expanded indication
- Palforzia® (peanut [Arachis hypogaea] allergen powder-dnfp) – Expanded indication
- Protonix® I.V. (pantoprazole) – Expanded indication
- Retevmo® (selpercatinib) – Expanded indications
- RSV vaccines – CDC updates RSV vaccination recommendations
- Brineura® (cerliponase alfa) – Expanded indication
- Brukinsa® (zanubrutinib) – New indication
- Wegovy® (semaglutide) – New indication
- Tagrisso® (osimertinib) – Expanded indication
- Darzalex Faspro® (daratumumab/hyaluronidase-fihj) – New indication
- Jemperli (dostarlimab-gxly) – Expanded indication
- Skyrizi® (risankizumab-rzaa) – New indication
- GLP-1 receptor agonist update – Tirzepatide for obstructive sleep apnea
- Velphoro® (sucroferric oxyhydroxide) – Expanded indication
- Victoza® (liraglutide) – First-time authorized brand alternative
- Voquezna® (vonoprazan) – New indication
- Vyvgart® Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) – New indication
- Wakix® (pitolisant) – Expanded indication
- Zoryve® (roflumilast) – New indication, new strength
- Udenyca® Onbody™ (pegfilgrastim-cbqv) – New biosimilar approval
- Alhemo® (concizumab-mtci) – New orphan drug approval
- Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) – New orphan drug approval
- Amtagvi™ (lifileucel) – New orphan drug approval
- Anktiva® (nogapendekin alfa inbakicept-pmln) – New drug approval
- Aqneursa™ (levacetylleucine) – New drug approval
- Attruby™ (acoramidis) – New orphan drug approval
- Aucatzyl® (obecabtagene autoleucel) – New orphan drug approval
- Aurlumyn™ (iloprost) – New orphan drug approval
- Avtozma® (tocilizumab-anoh) – New biosimilar approval
- Beqvez™ (fidanacogene elaparvovec-dzkt) – New orphan drug approval
- Bimzelx® (bimekizumab-bkzx) – New device approvals
- Bizengri® (zenocutuzumab-zbco) – New orphan drug approval
- Bkemv™ (eculizumab-aeeb) – New first-time interchangeable biosimilar approval
- Brynovin™ (sitagliptin) – New drug approval
- Clobetasol propionate ophthalmic suspension – New drug approval
- Cobenfy™ (xanomeline and trospium hydrochloride) – New drug approval
- Crenessity™ (crinecerfont) – New orphan drug approval
- Cyltezo® (adalimumab-adbm) – Correction - high concentration formulation approved as biosimilar, not interchangeable
- Danziten (nilotinib) – New drug approval
- Datroway® (datopotamab deruxtecan-dlnk) – New drug approval
- Duvyzat™ (givinostat) – New orphan drug approval
- Ebglyss™ (lebrikizumab-lbkz) – New drug approval
- Edurant ® (rilpivirine) – Expanded indication and new formulation
- Emrosi™ (minocycline) – New drug approval
- Ensacove™ (ensartinib) – New drug approval
- Entresto® Sprinkle (sacubitril/valsartan) – New formulation approval
- Eohilia™ (budesonide) – New orphan drug approval
- Exblifep® (cefepime/enmetazobactam) – New drug approval
- FluMist® (influenza vaccine live) – Self-administration approval
- Grafapex™ (treosulfan) – New orphan drug approval
- Hercessi™ (trastuzumab-strf) – New biosimilar approval
- Hympavzi™ (marstacimab-hncq) – New orphan drug approval
- Hyqvia® (immune globulin infusion 10% [human] with recombinant human hyaluronidase) – New orphan indication
- Imdelltra™ (tarlatamab-dlle) – New drug approval
- Imkeldi (imatinib) – New drug approval
- Imuldosa™ (ustekinumab-srlf) – New biosimilar approval
- Ingrezza® Sprinkle (valbenazine) – New formulation approval
- Itovebi™ (inavolisib) – New drug approval
- Journavx™ (suzetrigine) – New drug approval
- Jubbonti® (denosumab-bbdz) – New first-time interchangeable biosimilar approval
- Kebilidi (eladocagene exuparvovec-tneq) – New orphan drug approval
- Lenmeldy™ (atidarsagene autotemcel) – New orphan drug approval
- Letybo (letibotulinumtoxinA-wlbg) – New drug approval
- Libervant™ (diazepam) – New drug approval
- Miplyffa™ (arimoclomol) – New orphan drug approval
- Myhibbin (mycophenolate mofetil) – New drug approval
- Ocrevus Zunovo™ (ocrelizumab/hyaluronidase-ocsq) – New subcutaneous formulation approval
- Ojemda™ (tovorafenib) – New orphan drug approval
- Opdivo® (nivolumab) – New indication
- Opsynvi® (macitentan/tadalafil) – New orphan drug approval
- Opuviz™ (aflibercept-yszy) and Yesafili™ (aflibercept-jbvf)– New first-time interchangeable biosimilar approvals
- Orlynvah™ (sulopenem etzadroxil/probenecid) – New drug approval
- Osenvelt® (denosumab-bmwo) – New biosimilar approval
- Otulfi™ (ustekinumab-aauz) – New biosimilar approval
- Pavblu™ (aflibercept-ayyh) – New biosimilar approval
- Pavblu™ (aflibercept-ayyh) – New biosimilar launch
- Pivya™ (pivmecillinam) – New drug approval
- Retevmo® (selpercatinib) – New formulation approval
- Revuforj® (revumenib) – New orphan drug approval
- Rezdiffra™ (resmetirom) – New drug approval
- Rezenopy (naloxone) – New drug approval
- Rinvoq® (upadacitinib), Rinvoq LQ (upadacitinib) – New formulation approval, New/expanded indications
- Risvan® (risperidone) – New drug approval
- Ryoncil® (remestemcel-L-rknd) – New orphan drug approval
- Selarsdi™ (ustekinumab-aekn) – New biosimilar approval
- Simlandi® (adalimumab-ryvk) – New biosimilar approval
- Simlandi® (adalimumab-ryvk) – New biosimilar launch
- Steqeyma® (ustekinumab-stba) – New biosimilar approval
- Stoboclo® (denosumab-bmwo) – New biosimilar approval
- Symbravo® (meloxicam/rizatriptan) – New drug approval
- Tecelra® (afamitresgene autoleucel) – New orphan drug approval
- Tecentriq Hybreza™ (atezolizumab/hyaluronidase-tqjs) – New subcutaneous formulation approval
- Tevimbra® (tislelizumab-jsgr) – New drug approval
- Tryngolza™ (olezarsen) – New orphan drug approval
- Tryvio™ (aprocitentan) – New drug approval
- Tyenne® (tocilizumab-aazg) – New biosimilar approval
- Tyenne® (tocilizumab-aazg) – First-time biosimilar launch
- Udenyca® Onbody™ (pegfilgrastim-cbqv) – First-time biosimilar launch
- Unloxcyt™ (cosibelimab-ipdl) – New drug approval
- Vafseo® (vadadustat) – New drug approval
- Vijoice® (alpelisib) – New formulation approval
- Voydeya™ (danicopan) – New orphan drug approval
- Vyalev™ (foscarbidopa/foslevodopa) – New drug approval
- Vyloy® (zolbetuximab-clzb) – New orphan drug approval
- Winrevair™ (sotatercept) – New orphan drug approval
- Wyost® (denosumab-bbdz) – New first-time interchangeable biosimilar approval
- Xolremdi™ (mavorixafor) – New orphan drug approval
- Xromi (hydroxyurea) – New drug approval
- Yesintek™ (ustekinumab-kfce) – New biosimilar approval
- Zelsuvmi™ (berdazimer) – New drug approval
- Zevtera (ceftobiprole medocaril sodium) – New drug approval
- Ziihera® (zanidatamab-hrii) – New orphan drug approval
- Ahzantive™ (aflibercept-mrbb) – New biosimilar approval
- Capvaxive™ (pneumococcal 21-valent conjugate vaccine) – New vaccine approval
- Chewtadzy (tadalafil) – New drug approval
- Crexont® (carbidopa/levodopa) – New drug approval
- Elevidys® (delandistrogene moxeparvovec-rokl) – Accelerated approval converted to traditional approval, expanded indication
- Enzeevu™ (aflibercept-abzv) – New biosimilar approval
- Epysqli® (eculizumab-aagh) – New biosimilar approval
- Erzofri®™ (paliperidone palmitate) – New drug approval
- Iqirvo® (elafibranor) – New orphan drug approval
- Kisunla™ (donanemab-azbt) – New drug approval
- Lazcluze™ (lazertinib) – New drug approval, Rybrevant® (amivantamab) – New indication
- Leqselvi™ (deuruxolitinib) – New drug approval
- Livdelzi® (seladelpar) – New orphan drug approval
- Lymphir™ (denileukin diftitox-cxdl) – New orphan drug approval
- mRESVIA™ (respiratory syncytial virus vaccine) – New vaccine approval
- neffy® (epinephrine) – New drug approval
- Nemluvio® (nemolizumab-ilto) – New drug approval
- Niktimvo™ (axatilimab-csfr) – New orphan drug approval
- Nypozi™ (filgrastim-txid) – New biosimilar approval
- Ohtuvayre™ (ensifentrine) – New drug approval
- Onyda™ XR (clonidine) – New drug approval
- Opdivo Qvantig™ (nivolumab/hyaluronidase-nvhy) – New formulation approval
- Piasky (crovalimab-akkz) – New orphan drug approval
- Pyzchiva® (ustekinumab-ttwe) – New biosimilar approval
- Rytelo™ (imetelstat) – New orphan drug approval
- Sofdra™ (sofpironium) – New drug approval
- Yorvipath® (palopegteriparatide) – New orphan drug approval
- Tezruly™ (terazosin) – New formulation approval
- Tyenne® (tocilizumab-aazg) – New biosimilar formulation launch
- Vigafyde™ (vigabatrin) – New orphan drug approval
- Voranigo® (vorasidenib) – New orphan drug approval
- Yimmugo® (immune globulin intravenous, human - dira) – New drug approval
- Zunveyl® (benzgalantamine) – New drug approval
- Zurnai™ (nalmefene) – New drug approval
- Insight – Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray
- Astellas – Recall of Astagraf XL® and Prograf® capsules
- AvKARE– Recall of atovaquone oral suspension
- Bionpharma – Recall of atovaquone oral suspension
- Hospira – Recall of bleomycin injection
- Hospira – Recall of buprenorphine injection and labetalol injection
- EpiHealth declares bankruptcy – Recalls Cloderm® (clocortolone pivalate) and Minolira™ (minocycline)
- Endo – Expanded recall of clonazepam orally disintegrating tablets
- XGen Pharmaceuticals – Recall of cyclophosphamide injection
- Brassica Pharma – Recall of eye ointment products
- Alvogen – Recall of fentanyl transdermal system
- Eugia – Recall of methocarbamol injection
- Reckitt/Mead Johnson Nutrition – Recall of Nutramigen™ Powder
- B. Braun Medical– Recall of potassium chloride for injection
- Haleon – Recall of Robitussin® Honey CF Max products
- Dr. Reddy’s – Recall of sapropterin powder for oral solution
- Ascent Consumer Products – Recall of SinuCleanse® Soft Tip Squeeze Bottle Nasal Wash System
- Hospira – Recall of sodium bicarbonate and atropine injection products
- Alcon – Recall of Systane® eye drops
- Par Pharmaceutical – Recall of treprostinil injection
- Amneal – Recall of vancomycin oral solution
- Gilead – Recall of Veklury® (remdesivir) injection
- Azurity – Recall of Zenzedi® (dextroamphetamine)
- Roche – Recall of Accu-Chek® Guide Meter
- Hikma – Recall of acetaminophen injection
- Endo – Recall of clonazepam orally disintegrating tablets
- Endo – Expanded recall of clonazepam orally disintegrating tablets (ODT)
- Sagent – Recall of docetaxel injection
- Abbott– Recall FreeStyle Libre® 3 Sensors
- Baxter – Recall of heparin sodium injection
- Medtronic – Recall of MiniMed™ 600 series or 700 series insulin pumps
- Glenmark – Recall of potassium chloride extended-release capsules
- American Health Packaging – Recall of potassium chloride extended-release capsules
- B. Braun Medical – Recall of sodium chloride injection
- Glatiramer acetate – Boxed warning added
- FDA evaluates reports of suicidal thoughts or actions in patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
- Ocaliva® (obeticholic acid) – FDA drug safety communication
- FDA safety update – Prolia® (denosumab)
- Skysona™ (elivaldogene autotemcel) – FDA drug safety communication
- Veozah® (fezolinetant) – Boxed warning added
- FDA authorizes foreign importation of Bicillin® L-A (penicillin G benzathine)
- Jesduvroq® (daprodustat) – Withdrawal from the market
- Pfizer – Withdrawal of Oxbryta® (voxelotor) tablets
- PreHevBrio® (hepatitis B vaccine [recombinant]) – Discontinuation and withdrawal from the market
- Mitsubishi Tanabe – Discontinuation of Radicava® (edaravone) intravenous
- Relyvrio® (sodium phenylbutyrate/taurursodiol) – Drug discontinuation
- Takeda – Withdrawal of Vonvendi® (von Willebrand factor, recombinant)
- Namzaric® (memantine/donepezil) – First-time generic
- Oxtellar XR® (oxcarbazepine) – First-time generic
- Sprycel® (dasatinib) – First-time generic
- Thiola EC® (tiopronin) – First-time generic
- Alrex® (loteprednol) – First-time generic
- BromSite® (bromfenac) – First-time generic
- Emflaza® (deflazacort) – First-time generic
- EstroGel® (estradiol) – First-time generic
- Gralise® (gabapentin) – First-time generic
- Halaven® (eribulin) – First-time generic
- Indocin® (indomethacin) – First-time generic
- Korlym® (mifepristone) – First-time generic
- Motegrity® (prucalopride) – First-time generic
- Myrbetriq® (mirabegron) – First-time generic launch halted
- Nascobal® (cyanocobalamin) – First-time generic
- Prolensa® (bromfenac) – First-time generic
- Purixan® (mercaptopurine) – First-time generic
- Rectiv® (nitroglycerin) – First-time generic
- Sandostatin® LAR Depot (octreotide) – First-time generic
- Stendra® (avanafil) – First-time generic
- Victoza® (liraglutide) – First-time A-rated generic launch
- Auryxia® (ferric citrate) – First-time authorized generic alternative
- Corlanor® (ivabradine) – First-time generic
- Endari™ (l-glutamine) – First-time generic
- Lucemyra® (lofexidine) – First-time generic
- Somatuline® Depot (lanreotide) – First-time generic
- RxHighlights - April 2024 Edition
- RxHighlights - January 2024 Edition
- RxHighlights - March 2024 Edition
- RxHighlights - February 2024 Edition
- RxHighlights - September 2024 Edition
- RxHighlights - August 2024 Edition
- RxHighlights - May 2024 Edition
- RxHighlights - December 2024 Edition
- RxHighlights - July 2024 Edition
- RxHighlights - June 2024 Edition
- RxHighlights - November 2024 Edition
- RxHighlights - October 2024 Edition
- RxOutlook - 1st Quarter 2024
- RxOutlook - 2nd Quarter 2024
- RxOutlook - 3rd Quarter 2024
- RxOutlook - 4th Quarter 2024
- Long term care pharmacy attestation form
- Pharmacy Provider Relations Intake Form
- Network Participation Request form
- MAC appeal submission guide
- Submitting an electronic prior authorization to OptumRx
- Provider manual
- Specialty Management Access Portal user guide
- Medicare drug coverage and your rights
- UM Clinical Criteria Updates
- Prior Authorization Guidelines and Procedures
- RX Professionals Resources and Support
- Dovato (dolutegravir/lamivudine) – Expanded indication
- Livmarli® (maralixibat) – Expanded indication, new strength
- Abecma® (idecabtagene vicleucel) – Expanded indication
- Abrysvo® (respiratory syncytial virus vaccine) – New indication
- ACAM2000™ (smallpox and mpox (vaccinia) vaccine, live) – New indication
- Alecensa® (alectinib) – New indication
- Balversa® (erdafitinib) – Updated indication, accelerated approval converted to full approval
- Besponsa™ (inotuzumab ozogamicin) – Updated indication
- Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) – Expanded indication
- Bimzelx® (bimekizumab) – New indications
- Bimzelx® (bimekizumab-bkzx) – New indication
- Braftovi® (encorafenib) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Calquence® (acalabrutinib) – New indication, accelerated approval converted to traditional approval
- landing
- UnitedHealthcare Community Plan of Delaware
- UnitedHealthcare Community Plan of Indiana
- UnitedHealthcare Community Plan of Iowa
- UnitedHealthcare Community Plan of Kansas
- UnitedHealthcare Community Plan of Kentucky
- UnitedHealthcare Community Plan of Michigan
- UnitedHealthcare Community Plan of Nebraska
- OptumRx New Jersey Provider Information
- Health Care Professionals Portal Terms of Use
- Carvykti® (ciltacabtagene autoleucel) – Expanded indication
- Casgevy™ (exagamglogene autotemcel) – New orphan indication
- Cimzia® (certolizumab pegol) – New indication
- Pfizer/BioNTech, Moderna, and Novavax COVID-19 vaccines (Omicron variant XBB.1.5) – CDC recommends an additional vaccine dose in 65 years and older
- COVID-19 vaccines – ACIP recommends additional 2024-2025 vaccine doses for certain groups
- Dupixent® (dupilumab) – Expanded indication
- Dupixent® (dupilumab) – Expanded indication
- Dupixent® (dupilumab) for COPD – New indication approval
- Enhertu® (fam-trastuzumab deruxtecan-nxki) – New indication
- Enhertu® (trastuzumab deruxtecan) – Expanded indication
- Entyvio® (vedolizumab) – New indication for subcutaneous use
- Fanapt® (iloperidone) – New indication
- Farxiga® (dapagliflozin) – First-time authorized brand alternative
- Fasenra® (benralizumab) – Expanded indication
- Fasenra® (benralizumab) – New indication
- Filspari® (sparsentan) – Updated indication, accelerated approval converted to full approval
- Gammagard Liquid® (immune globulin infusion [human] 10% solution) – New indication
- Gemtesa® (vibegron) – New indication
- Iclusig® (ponatinib) – Expanded indication
- Imcivree® (setmelanotide) – Expanded indication
- Imfinzi® (durvalumab) – New indication
- Invokana® (canagliflozin), Invokamet/Invokamet® XR (canagliflozin/metformin) – Expanded indication
- Ixinity® (coagulation factor IX [recombinant]) – Expanded indication
- Keytruda® (pembrolizumab) – Expanded indication
- Keytruda® (pembrolizumab) – Updated indication, accelerated approval converted to full approval
- Keytruda® (pembrolizumab) – New indication
- Kisqali® (ribociclib) – New indication
- Livmarli® (maralixibat) – New indication
- Lumakras® (sotorasib) plus Vectibix® (panitumumab) – New indication
- Lumryz™ (sodium oxybate) – Expanded indication
- Lutathera® (lutetium Lu 177 dotatate) – Expanded indication
- Mircera® (methoxy polyethylene glycol-epoetin beta) – Expanded indication
- Moderna COVID-19 Vaccine – Expanded emergency use authorization
- Nemluvio® (nemolizumab-ilto) – New indication
- Nexletol® (bempedoic acid), Nexlizet® (bempedoic acid/ezetimibe) – New/expanded indications
- Novavax COVID-19 vaccine, adjuvanted (2024-2025 formula) – Emergency Use Authorization
- Odactra® (Dermatophagoides farinae and Dermatophagoides pteronyssinus) – Expanded indication
- Omvoh® (mirikizumab-mrkz) – New indication
- Onivyde® (irinotecan liposome injection) – New indication
- Opdivo® (nivolumab) – New indication
- Otezla® (apremilast) – Expanded indication
- Ozempic® (semaglutide) – New indication
- Pemgarda™ (pemivibart) – Emergency use authorization approval
- Piqray® (alpelisib) – Expanded indication
- Praluent® (alirocumab) – Expanded indication
- Prevymis® (letermovir) – Expanded indication, new dosage formulation
- Rybrevant® (amivantamab-vmjw) – New indication, accelerated approval converted to full approval
- Rybrevant® (amivantamab-vmjw) – New indication
- Sarclisa® (isatuximab-irfc) – New indication
- Scemblix® (asciminib) – New indication
- Selarsdi™ (ustekinumab-aekn) – New indications and formulation approval
- Soliris® (eculizumab) – Expanded indication
- Spevigo® (spesolimab-sbzo) – Expanded indication
- Spravato® (esketamine) – Expanded indication
- Tagrisso® (osimertinib) – New indication
- Tevimbra® (tislelizumab-jsgr) – New indication
- Tremfya® (guselkumab) – New indication
- Trikafta® (elexacaftor/tezacaftor/ivacaftor; ivacaftor) – Updated label, boxed warning added
- Trodelvy™ (sacituzumab govitecan-hziy) – Indication withdrawal
- Ultomiris® (ravulizumab-cwvz) – New indication
- Veklury® (remdesivir) – Expanded indication
- Vemlidy® (tenofovir alafenamide) – New indication
- Vtama® (tapinarof) – New indication
- Xhance® (fluticasone propionate) – New indication
- Xigduo® XR (dapagliflozin/metformin) – First-time authorized brand alternative
- Xofluza® (baloxavir marboxil) – Expanded indication
- Xolair® (omalizumab) – New indication
- Zepbound® (tirzepatide) – New indication
- Arexvy® (respiratory syncytial virus vaccine) – Expanded indication
- Arixtra® (fondaparinux) – New indication
- Augtyro™ (repotrectinib) – New indication
- Blincyto® (blinatumomab) – New indication
- Breyanzi® (lisocabtagene maraleucel) – New indication
- Comirnaty® and Spikevax® (KP.2) 2024 – 2025 vaccines – FDA approval and Emergency Use Authorization
- COVID-19 vaccines – FDA makes recommendations for new monovalent vaccine composition for 2024-2025
- COVID-19 vaccines – ACIP makes recommendations for 2024-2025 vaccine administration
- COVID-19 vaccines – VRBPAC makes recommendations for new monovalent vaccine composition
- Epkinly® (epcoritamab-bysp) – New indication
- Fabhalta® (iptacopan) – New indication
- Farxiga® (dapagliflozin), Xigduo® XR (dapagliflozin/metformin) – Expanded indication
- Fibryga® (fibrinogen [human]) – New indication
- Firdapse® (amifampridine) – Updated dosing
- Furoscix® (furosemide) – Expanded indication
- Imfinzi® (durvalumab) – New indication
- Imfinzi® (durvalumab) – New indication
- Imfinzi® (durvalumab) – New indication
- Kevzara® (sarilumab) – New indication
- Keytruda® (pembrolizumab) – New indication
- Kisqali® (ribociclib) – Updated indication
- Krazati® (adagrasib) – New indication
- Motpoly XR™ (lacosamide) – New indication
- Nexobrid® (anacaulase-bcdb) – Expanded indication
- Palforzia® (peanut [Arachis hypogaea] allergen powder-dnfp) – Expanded indication
- Protonix® I.V. (pantoprazole) – Expanded indication
- Retevmo® (selpercatinib) – Expanded indications
- RSV vaccines – CDC updates RSV vaccination recommendations
- Brineura® (cerliponase alfa) – Expanded indication
- Brukinsa® (zanubrutinib) – New indication
- Wegovy® (semaglutide) – New indication
- Tagrisso® (osimertinib) – Expanded indication
- Darzalex Faspro® (daratumumab/hyaluronidase-fihj) – New indication
- Jemperli (dostarlimab-gxly) – Expanded indication
- Skyrizi® (risankizumab-rzaa) – New indication
- GLP-1 receptor agonist update – Tirzepatide for obstructive sleep apnea
- Velphoro® (sucroferric oxyhydroxide) – Expanded indication
- Victoza® (liraglutide) – First-time authorized brand alternative
- Voquezna® (vonoprazan) – New indication
- Vyvgart® Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) – New indication
- Wakix® (pitolisant) – Expanded indication
- Zoryve® (roflumilast) – New indication, new strength
- Udenyca® Onbody™ (pegfilgrastim-cbqv) – New biosimilar approval
- Alhemo® (concizumab-mtci) – New orphan drug approval
- Alyftrek™ (vanzacaftor/tezacaftor/deutivacaftor) – New orphan drug approval
- Amtagvi™ (lifileucel) – New orphan drug approval
- Anktiva® (nogapendekin alfa inbakicept-pmln) – New drug approval
- Aqneursa™ (levacetylleucine) – New drug approval
- Attruby™ (acoramidis) – New orphan drug approval
- Aucatzyl® (obecabtagene autoleucel) – New orphan drug approval
- Aurlumyn™ (iloprost) – New orphan drug approval
- Avtozma® (tocilizumab-anoh) – New biosimilar approval
- Beqvez™ (fidanacogene elaparvovec-dzkt) – New orphan drug approval
- Bimzelx® (bimekizumab-bkzx) – New device approvals
- Bizengri® (zenocutuzumab-zbco) – New orphan drug approval
- Bkemv™ (eculizumab-aeeb) – New first-time interchangeable biosimilar approval
- Brynovin™ (sitagliptin) – New drug approval
- Clobetasol propionate ophthalmic suspension – New drug approval
- Cobenfy™ (xanomeline and trospium hydrochloride) – New drug approval
- Crenessity™ (crinecerfont) – New orphan drug approval
- Cyltezo® (adalimumab-adbm) – Correction - high concentration formulation approved as biosimilar, not interchangeable
- Danziten (nilotinib) – New drug approval
- Datroway® (datopotamab deruxtecan-dlnk) – New drug approval
- Duvyzat™ (givinostat) – New orphan drug approval
- Ebglyss™ (lebrikizumab-lbkz) – New drug approval
- Edurant ® (rilpivirine) – Expanded indication and new formulation
- Emrosi™ (minocycline) – New drug approval
- Ensacove™ (ensartinib) – New drug approval
- Entresto® Sprinkle (sacubitril/valsartan) – New formulation approval
- Eohilia™ (budesonide) – New orphan drug approval
- Exblifep® (cefepime/enmetazobactam) – New drug approval
- FluMist® (influenza vaccine live) – Self-administration approval
- Grafapex™ (treosulfan) – New orphan drug approval
- Hercessi™ (trastuzumab-strf) – New biosimilar approval
- Hympavzi™ (marstacimab-hncq) – New orphan drug approval
- Hyqvia® (immune globulin infusion 10% [human] with recombinant human hyaluronidase) – New orphan indication
- Imdelltra™ (tarlatamab-dlle) – New drug approval
- Imkeldi (imatinib) – New drug approval
- Imuldosa™ (ustekinumab-srlf) – New biosimilar approval
- Ingrezza® Sprinkle (valbenazine) – New formulation approval
- Itovebi™ (inavolisib) – New drug approval
- Journavx™ (suzetrigine) – New drug approval
- Jubbonti® (denosumab-bbdz) – New first-time interchangeable biosimilar approval
- Kebilidi (eladocagene exuparvovec-tneq) – New orphan drug approval
- Lenmeldy™ (atidarsagene autotemcel) – New orphan drug approval
- Letybo (letibotulinumtoxinA-wlbg) – New drug approval
- Libervant™ (diazepam) – New drug approval
- Miplyffa™ (arimoclomol) – New orphan drug approval
- Myhibbin (mycophenolate mofetil) – New drug approval
- Ocrevus Zunovo™ (ocrelizumab/hyaluronidase-ocsq) – New subcutaneous formulation approval
- Ojemda™ (tovorafenib) – New orphan drug approval
- Opdivo® (nivolumab) – New indication
- Opsynvi® (macitentan/tadalafil) – New orphan drug approval
- Opuviz™ (aflibercept-yszy) and Yesafili™ (aflibercept-jbvf)– New first-time interchangeable biosimilar approvals
- Orlynvah™ (sulopenem etzadroxil/probenecid) – New drug approval
- Osenvelt® (denosumab-bmwo) – New biosimilar approval
- Otulfi™ (ustekinumab-aauz) – New biosimilar approval
- Pavblu™ (aflibercept-ayyh) – New biosimilar approval
- Pavblu™ (aflibercept-ayyh) – New biosimilar launch
- Pivya™ (pivmecillinam) – New drug approval
- Rapiblyk (landiolol) – New drug approval
- Retevmo® (selpercatinib) – New formulation approval
- Revuforj® (revumenib) – New orphan drug approval
- Rezdiffra™ (resmetirom) – New drug approval
- Rezenopy (naloxone) – New drug approval
- Rinvoq® (upadacitinib), Rinvoq LQ (upadacitinib) – New formulation approval, New/expanded indications
- Risvan® (risperidone) – New drug approval
- Ryoncil® (remestemcel-L-rknd) – New orphan drug approval
- Selarsdi™ (ustekinumab-aekn) – New biosimilar approval
- Simlandi® (adalimumab-ryvk) – New biosimilar approval
- Simlandi® (adalimumab-ryvk) – New biosimilar launch
- Steqeyma® (ustekinumab-stba) – New biosimilar approval
- Stoboclo® (denosumab-bmwo) – New biosimilar approval
- Symbravo® (meloxicam/rizatriptan) – New drug approval
- Tecelra® (afamitresgene autoleucel) – New orphan drug approval
- Tecentriq Hybreza™ (atezolizumab/hyaluronidase-tqjs) – New subcutaneous formulation approval
- Tevimbra® (tislelizumab-jsgr) – New drug approval
- Tryngolza™ (olezarsen) – New orphan drug approval
- Tryvio™ (aprocitentan) – New drug approval
- Tyenne® (tocilizumab-aazg) – New biosimilar approval
- Tyenne® (tocilizumab-aazg) – First-time biosimilar launch
- Udenyca® Onbody™ (pegfilgrastim-cbqv) – First-time biosimilar launch
- Unloxcyt™ (cosibelimab-ipdl) – New drug approval
- Vafseo® (vadadustat) – New drug approval
- Vijoice® (alpelisib) – New formulation approval
- Voydeya™ (danicopan) – New orphan drug approval
- Vyalev™ (foscarbidopa/foslevodopa) – New drug approval
- Vyloy® (zolbetuximab-clzb) – New orphan drug approval
- Winrevair™ (sotatercept) – New orphan drug approval
- Wyost® (denosumab-bbdz) – New first-time interchangeable biosimilar approval
- Xolremdi™ (mavorixafor) – New orphan drug approval
- Xromi (hydroxyurea) – New drug approval
- Yesintek™ (ustekinumab-kfce) – New biosimilar approval
- Zelsuvmi™ (berdazimer) – New drug approval
- Zevtera (ceftobiprole medocaril sodium) – New drug approval
- Ziihera® (zanidatamab-hrii) – New orphan drug approval
- Ahzantive™ (aflibercept-mrbb) – New biosimilar approval
- Capvaxive™ (pneumococcal 21-valent conjugate vaccine) – New vaccine approval
- Chewtadzy (tadalafil) – New drug approval
- Crexont® (carbidopa/levodopa) – New drug approval
- Elevidys® (delandistrogene moxeparvovec-rokl) – Accelerated approval converted to traditional approval, expanded indication
- Enzeevu™ (aflibercept-abzv) – New biosimilar approval
- Epysqli® (eculizumab-aagh) – New biosimilar approval
- Erzofri®™ (paliperidone palmitate) – New drug approval
- Iqirvo® (elafibranor) – New orphan drug approval
- Kisunla™ (donanemab-azbt) – New drug approval
- Lazcluze™ (lazertinib) – New drug approval, Rybrevant® (amivantamab) – New indication
- Leqselvi™ (deuruxolitinib) – New drug approval
- Livdelzi® (seladelpar) – New orphan drug approval
- Lymphir™ (denileukin diftitox-cxdl) – New orphan drug approval
- mRESVIA™ (respiratory syncytial virus vaccine) – New vaccine approval
- neffy® (epinephrine) – New drug approval
- Nemluvio® (nemolizumab-ilto) – New drug approval
- Niktimvo™ (axatilimab-csfr) – New orphan drug approval
- Nypozi™ (filgrastim-txid) – New biosimilar approval
- Ohtuvayre™ (ensifentrine) – New drug approval
- Onyda™ XR (clonidine) – New drug approval
- Opdivo Qvantig™ (nivolumab/hyaluronidase-nvhy) – New formulation approval
- Piasky (crovalimab-akkz) – New orphan drug approval
- Pyzchiva® (ustekinumab-ttwe) – New biosimilar approval
- Rytelo™ (imetelstat) – New orphan drug approval
- Sofdra™ (sofpironium) – New drug approval
- Yorvipath® (palopegteriparatide) – New orphan drug approval
- Tezruly™ (terazosin) – New formulation approval
- Tyenne® (tocilizumab-aazg) – New biosimilar formulation launch
- Vigafyde™ (vigabatrin) – New orphan drug approval
- Voranigo® (vorasidenib) – New orphan drug approval
- Yimmugo® (immune globulin intravenous, human - dira) – New drug approval
- Zunveyl® (benzgalantamine) – New drug approval
- Zurnai™ (nalmefene) – New drug approval
- Insight – Recall of Americaine® 20% Benzocaine Topical Anesthetic Spray
- Astellas – Recall of Astagraf XL® and Prograf® capsules
- AvKARE– Recall of atovaquone oral suspension
- Bionpharma – Recall of atovaquone oral suspension
- Hospira – Recall of bleomycin injection
- Hospira – Recall of buprenorphine injection and labetalol injection
- EpiHealth declares bankruptcy – Recalls Cloderm® (clocortolone pivalate) and Minolira™ (minocycline)
- Endo – Expanded recall of clonazepam orally disintegrating tablets
- XGen Pharmaceuticals – Recall of cyclophosphamide injection
- Brassica Pharma – Recall of eye ointment products
- Alvogen – Recall of fentanyl transdermal system
- Eugia – Recall of methocarbamol injection
- Reckitt/Mead Johnson Nutrition – Recall of Nutramigen™ Powder
- B. Braun Medical– Recall of potassium chloride for injection
- Haleon – Recall of Robitussin® Honey CF Max products
- Dr. Reddy’s – Recall of sapropterin powder for oral solution
- Ascent Consumer Products – Recall of SinuCleanse® Soft Tip Squeeze Bottle Nasal Wash System
- Hospira – Recall of sodium bicarbonate and atropine injection products
- Alcon – Recall of Systane® eye drops
- Par Pharmaceutical – Recall of treprostinil injection
- Amneal – Recall of vancomycin oral solution
- Gilead – Recall of Veklury® (remdesivir) injection
- Azurity – Recall of Zenzedi® (dextroamphetamine)
- Roche – Recall of Accu-Chek® Guide Meter
- Hikma – Recall of acetaminophen injection
- Endo – Recall of clonazepam orally disintegrating tablets
- Endo – Expanded recall of clonazepam orally disintegrating tablets (ODT)
- Sagent – Recall of docetaxel injection
- Abbott– Recall FreeStyle Libre® 3 Sensors
- Baxter – Recall of heparin sodium injection
- Medtronic – Recall of MiniMed™ 600 series or 700 series insulin pumps
- Glenmark – Recall of potassium chloride extended-release capsules
- American Health Packaging – Recall of potassium chloride extended-release capsules
- B. Braun Medical – Recall of sodium chloride injection
- Glatiramer acetate – Boxed warning added
- FDA evaluates reports of suicidal thoughts or actions in patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
- Ocaliva® (obeticholic acid) – FDA drug safety communication
- FDA safety update – Prolia® (denosumab)
- Skysona™ (elivaldogene autotemcel) – FDA drug safety communication
- Veozah® (fezolinetant) – Boxed warning added
- FDA authorizes foreign importation of Bicillin® L-A (penicillin G benzathine)
- Jesduvroq® (daprodustat) – Withdrawal from the market
- Pfizer – Withdrawal of Oxbryta® (voxelotor) tablets
- PreHevBrio® (hepatitis B vaccine [recombinant]) – Discontinuation and withdrawal from the market
- Mitsubishi Tanabe – Discontinuation of Radicava® (edaravone) intravenous
- Relyvrio® (sodium phenylbutyrate/taurursodiol) – Drug discontinuation
- Takeda – Withdrawal of Vonvendi® (von Willebrand factor, recombinant)
- Namzaric® (memantine/donepezil) – First-time generic
- Oxtellar XR® (oxcarbazepine) – First-time generic
- Sprycel® (dasatinib) – First-time generic
- Thiola EC® (tiopronin) – First-time generic
- Alrex® (loteprednol) – First-time generic
- BromSite® (bromfenac) – First-time generic
- Emflaza® (deflazacort) – First-time generic
- EstroGel® (estradiol) – First-time generic
- Gralise® (gabapentin) – First-time generic
- Halaven® (eribulin) – First-time generic
- Indocin® (indomethacin) – First-time generic
- Korlym® (mifepristone) – First-time generic
- Motegrity® (prucalopride) – First-time generic
- Myrbetriq® (mirabegron) – First-time generic launch halted
- Nascobal® (cyanocobalamin) – First-time generic
- Prolensa® (bromfenac) – First-time generic
- Purixan® (mercaptopurine) – First-time generic
- Rectiv® (nitroglycerin) – First-time generic
- Sandostatin® LAR Depot (octreotide) – First-time generic
- Stendra® (avanafil) – First-time generic
- Victoza® (liraglutide) – First-time A-rated generic launch
- Auryxia® (ferric citrate) – First-time authorized generic alternative
- Corlanor® (ivabradine) – First-time generic
- Endari™ (l-glutamine) – First-time generic
- Lucemyra® (lofexidine) – First-time generic
- Somatuline® Depot (lanreotide) – First-time generic
- RxHighlights - April 2024 Edition
- RxHighlights - January 2024 Edition
- RxHighlights - March 2024 Edition
- RxHighlights - February 2024 Edition
- RxHighlights - September 2024 Edition
- RxHighlights - August 2024 Edition
- RxHighlights - May 2024 Edition
- RxHighlights - December 2024 Edition
- RxHighlights - July 2024 Edition
- RxHighlights - June 2024 Edition
- RxHighlights - November 2024 Edition
- RxHighlights - October 2024 Edition
- RxOutlook - 1st Quarter 2024
- RxOutlook - 2nd Quarter 2024
- RxOutlook - 3rd Quarter 2024
- RxOutlook - 4th Quarter 2024
- Long term care pharmacy attestation form
- Pharmacy Provider Relations Intake Form
- Network Participation Request form
- MAC appeal submission guide
- Submitting an electronic prior authorization to OptumRx
- Provider manual
- Specialty Management Access Portal user guide
- Medicare drug coverage and your rights
- Prior Authorization Guidelines and Procedures
- Rapiblyk (landiolol) – New drug approval
- Healthcare Industry Insights | Optum Business
- Time to Outsource Workers Compensation Payments
- Driving Healthcare Innovation
- Data and Analytics Trends & Insights | Optum Business
- Healthcare Finances & Payments Insights | Optum Business
- Mental Health Insights | Optum Business
- Patient & Member Engagement Insights | Optum Business
- Pharmacy Management Insights | Optum Rx Business
- Technology & Automation | Optum Business
- Value-Based Care Insights | Optum Business
- C-suite Insights for Healthcare Executives | Optum Business
- Subscribe C-Suite Insights and Weekly Briefing | Optum
- Tackle the Workforce Crisis with Human Innovation [White Paper]
- 7 Strategies to Meet All Mental Health Needs
- Q&A: A Value-Based Care Path Forward
- Webinar: Connected Communities to Advance Population Health
- Success Story: Strong Financial Future Through Partnership
- 6 Workforce Strategies for Healthcare Leaders
- Mental Health Data: Addressing the Great Information Divide
- Addressing the Root Causes of Mental Health Disparities
- Webinar: Operating Imperatives for Value-Based Care
- Connected Care: See the Full Picture for Whole-Person Health
- 4 Key Forces Shaping the Future of Pharmacy
- E-book: Fitness for a Generation That Never Gets Old
- Forging a New Frontier in Mental & Behavioral Health
- E-book: 5 Ways to Lower the Total Cost of Pharmacy Care
- Using Data to Monitor Behavioral Health Services
- Q&A: Impacting SDOH for Patients & Communities
- Supporting Providers in the Transition to Value-Based Care
- Hub Benefits Strategy: What Employers Need to Know
- 5 Strategies: Health Equity in Kidney Disease Management
- Analytics in Payer-Oncologist Partnerships
- Closing the Diagnosis Gap in Chronic Kidney Disease
- E-book: The Role of Navigation in Simplifying Healthcare
- 3 Ways Digital Movement Is Reshaping Member Experiences
- How to Eliminate Prescription Waste
- White Paper: How to Manage Blockbuster Anti-Obesity Drugs
- How to Manage Medication Overload
- E-book: 6 Trends Shaping Pharma Strategies in 2024
- 2023 Trends Shaping Life Sciences Strategies
- E-book: What Gen Z Wants in Employer Fitness Benefits
- Catalyze the Use of RWE in the Life Sciences Industry
- How to Maximize the ROI of Real-World Data
- Curated Genomics Data to Advance Discovery & Treatment
- Steps to Harness Disparate Data for Federal Agencies
- Maternal Mental Health Crisis: How Payers & Employers Can Help
- Recognize What Is and Isn't Captured in Real-World Data (RWD)
- White Paper: Human-Centered Design in Healthcare
- Natural Language Processing Methods for Optum Clinical Data
- What If Providers’ Clinical Data Were Research-Ready?
- White Paper: Help Physicians Spend More Time with Members
- Integrated Real-World Data: The Key to Accelerating Innovation
- Maximize Your Real-World Data (RWD) Strategy
- Using the Right Real-World Data Tools in Research
- Addressing Pharmacy Issues That Matter to You
- Maximizing Success of Centralized Real-World Data Teams
- Orphan Drugs Are Sweeping the Market: Can We Afford Them?
- Break Down Silos in Clinical Trial & Protocol Design
- Reassessing the Inflation Reduction Act with Real-World Evidence
- A Seamless Pharmacy Benefit Change? [Case Study]
- Health Equity Vision into Action Report
- Pilot Program Lowers Cardiovascular Disease Risk
- Supporting Veteran Truckers with a Whole-Health Approach
- 4 Ways Digital Claim Payments Can Save You Money
- Teaming Up with Task Force Movement for Health & Well-Being
- Telephone Lifestyle Coaching Program for Veterans
- Deliver Program Integrity Efficiencies
- Reduce Fraud, Waste & Abuse: Partnering with Federal Agencies
- Alzheimer’s Treatment: Time for a Level-Set?
- 3 Steps to Slash Medication Costs for Employers
- 4 Ways Small & Emerging Biopharma Can Harness RWD
- E-book: Make Your Pharmacy Benefit Plan Work Better
- Case Study: Excel Medical Center Improves Patient Outcomes
- Increasing Potential of Genomic Data in Life Sciences
- Expanding Health Equity in Clinical Trials: A Conversation
- Identifying Patients at Risk for Bone Fracture Within 2 Years
- White Paper: Gain Insights to Restore Financial Health
- Slowing the Specialty Pharmacy Carve-Out Stampede
- Actionable Analytics: How States Can Achieve Health Equity
- Evidence-Based Clinical Practice Guidelines for DoD and VA
- Global Nurse Advice Line for Federal Health Agency Programs
- Automate Fraud, Waste & Abuse to Improve Program Integrity
- Robotic Process Automation for Federal Government Programs
- Visualizing Fraud, Waste & Abuse to Drive Program Integrity
- Alternative Funding: Real Savings or Real Problems?
- 8 Ways to Make Drugs More Affordable
- 8 Ways to Make Drugs More Affordable
- E-book: Is Your Pharmacy Benefit Manager Delivering Value?
- Gene Therapies: Can We Afford the Future of Medicine?
- Optum Rx Pharmacy Insights Podcast
- How Pharmacy Benefit Managers Add Value, Lower Costs
- Making Risk Adjustment Programs Work for You
- Bassett Healthcare Network Blazes a Bold Path Forward
- Video Series: Bassett Healthcare Partnering
- Achieve Accuracy and Efficiency in Claim Pricing
- Best Practices for Reducing Provider Abrasion
- Best Practices for Identifying and Recovering Overpayments
- Boulder Community Health and Optum: Benefits of Partnership
- The Importance of Staying Current in Your Core Admin Platform
- Validating Short-Stay Hospital Bills
- Claim Review: How to Adopt Best Practices
- StepWise Application Migration to the Cloud [Case Study]
- Payment Integrity Best Practices to Maximize Savings
- Moving to Lower-Cost Electronic Payments [Case Study]
- Achieving Health Equity: Strategies for Payers
- Optum Rx Client Testimonial: Wespath Institutional Investments
- Optum Social Care Assistance Helps Health Plans
- Proactive Dual Eligible Medicaid Renewal
- Redefining the Prior Authorization Process
- How to Contain Costs for GLP-1 Anti-Obesity Drugs
- Video: Optum Rx Customer Obsession
- Fighting Fraud: How a Plan Sponsor Recovered $315,000
- The Dangers of Polypharmacy Explained
- New Billing System Improves Financial Performance
- Financial Performance Resources for Health Leaders
- Medical Necessity Denials – Untangle the Causes
- Webinar: Impacting Medical Loss Ratio | AHIP 2023
- Let’s Talk: Latest Takes in the Life Sciences Industry
- How Hospitals Can Maintain Operational and Financial Viability
- Informing FDA Biologics Effectiveness & Safety (BEST) Initiative
- Boost Efficiency with Payment Optimization
- Insights in Claims Payment Processing
- Tip Sheet: Accounts Receivable Recovery Outsourcing
- A/R Recovery Services Provide Revenue Continuity
- Front Door Strategy Improves Patient Experience
- 6 Guiding Tips for Selecting a Fit for Purpose Data Set
- Health Leaders Share IT Transformation Stories
- The Connection Between Money and Health
- White Paper: Toward Outcomes-Based Payments
- Improving SGLT2i Therapy Adherence for Patients [Case Study]
- 4 Reasons You Should Prioritize Digital Payments
- Take Action & Maximize Impact Using Real-World Data Assets
- How Optum Supports Value-Based Goals with Powerful Products
- Facing Revenue Cycle Challenges Within a Depressed Labor Market
- Promoting Access to Gene Therapies for Rare Disorders
- How to Leverage AI to Reduce Administrative Variation
- Strategies for Improving Front-End Revenue Cycle for Providers
- Telehealth Trends and Challenges [Webinar]
- Invest for Revenue Cycle Success in Challenging Times
- Smartest Revenue Cycle Investments for Healthcare
- 10 Hurdles to Reimbursement [E-book]
- Advanced Pharmacy Audit Services
- Buck Denial Trends
- A Drill-Down Strategy to Decrease Denials
- 2024 Revenue Cycle Denials Index
- Behavioral Health Provider Digital Access Survey
- Achieving Compliant Coverage Identification
- Optum Wins 2023 Enabling Technology Leadership Award
- Easier Access to Mental Health Care with Digital Scheduling
- How the Revenue Cycle and Leaders Are Evolving
- Benefits of Artificial Intelligence Reach the Revenue Cycle
- Develop Your Growth Strategy Using Optum Market Advantage
- Infographic: How Poor Market Visibility Hampers Growth
- Support Risk Adjustment with AI-Driven CDI Technology
- Get Competitive with CDI and Coding Analytics
- Exploring New Possibilities with CDI Metrics
- Biosimilars to Save Billions in This Decade
- Defending Emergency Department Reimbursement
- Copay Cards & How to Avoid Pharmacy Benefit Disruption
- Developing a Best-in-Class Middle Revenue Cycle for Hospitals
- Focus on Patients Not Paperwork with AI
- Focus on Patients, Not Paperwork, with AI | Optum
- Improve Coding Efficiency with Optum CAC & CDI 3D
- Improving Clinical Documentation Improvement (CDI) Efficiency
- 3 Ways to Deal with Escalating Drug Costs
- Everest Group Names Optum 2023 Patient Engagement Leader
- Annual Survey on Consumer Care Preferences
- Digital Scheduling at a Rural Health System
- Driving to a Healthier Bottom Line Through UM Optimization
- The Physician Liaison Outreach Playbook
- Payer Channel Scheduling: Boost Your Health System’s Reach
- Uncover Site Connections with Data-Driven Heat Maps
- Empowering Rx Clients with Choice & Transparency
- Self-Scheduling Boosts Access and Reduces Staff Burden
- Virtual Urgent Care Scheduling for Telehealth
- First Big Drugs of 2024: Optum Rx Drug Pipeline Insights Report
- Online Scheduling for COVID-19 Vaccinations
- A Young Patient’s Hemophilia Story
- Provider Telehealth Use and Experience Survey
- How to Remove Roadblocks to Behavioral Health
- Addressing Challenges with CDI and Coding
- White Paper: Smart Formulary Management
- The Financial Case for Connected Care
- How AI Can Help Fraud Investigations
- White Paper: Real-World Data Fills Rare Disease Data Gaps
- Is Your Real-World Data Research Ready?
- Using Epidemiological Data to Build Public Confidence
- Enabling Outcome-Based Contracts for Gene Therapies
- How Race & Ethnicity Data Help Bridge Health Equity Gap
- Five Step InterQual Evidence-Based Process
- E-book: Assessing Drug Performance with Integrated Data
- Webinar: Solving Clinical Trial Recruitment Challenges with Data
- U.S. Military Entrance Processing Command for Active Duty
- Applying Robotic Process Automation for Compliance
- Success Through Redesigning and Automating UM
- Success Through Redesigning and Automating UM
- AI and Clinical Decision-Making
- The ASAM Criteria® Navigator, 4th Edition
- The ASAM Criteria® Navigator, 4th edition | Optum
- Physician Outreach Toolkit
- Clinical Exchange ePrescribe Self-Service Tool
- Improved Arkansas Medicaid Outcomes
- Medicaid and CHIP Federal Quality Measures
- Medicaid and CHIP Federal Quality Measures | Optum
- Arkansas’ New Approach to Medicaid Management
- 9 Key Ways to Modernize the Medicaid Experience
- 9 Key Ways to Modernize the Medicaid Experience | Optum
- Value Assessment Frameworks: A Conversation
- Medicare Content Navigator and InterQual Transparency
- InterQual AutoReview for Optimizing UM
- InterQual Follows the Science & Defends Against Bias
- 5 Things a Claim Review Program Does
- Workplace Fitness Benefits: What Every Employer Should Know
- Antiracism and Inclusion
- White Paper: Symmetry EBM Connect
- Symmetry Oncology Analytics
- How to Make the Most of Your Fitness Benefits
- Drug Pricing Report Spotlight: Wound Care
- Critical Steps to Navigating Change Management
- Precision Medicine Trends: A Conversation with Chris Boone
- The New Drugs Plan Sponsors Need to Watch For
- How Clinicogenomics Linked Data Advances Research
- Orphan Drug Market: Rare Diseases, Large Costs
- 2024 Star Ratings Preview
- How Health Equity Can Be a Catalyst for Growth
- Why Quality Fitness Benefits Are Crucial for Employers
- 3 Ways to Beat Vaccine Fatigue
- Improve Women’s Health with Community-Based Solutions
- Rules Impacting Pharmacy: Spring 2024 Legislative Sessions
- Digital Equity Across the Healthcare System
- Digital Equity Across the Healthcare System | Optum
- 2023 3rd Annual C-suite Research Report
- Microservice Imaging Architecture
- Cost Breakthroughs in Complex Care Management
- HouseCalls Helps Care for Medicare Advantage Members at Home
- Defragment Health Care with In-Home Assessments
- Extending an Independent Lifestyle for Seniors
- Upgrade as a Service for Health Plans
- The New Landscape of Fertility Benefits: 5 Things to Know
- Help Improve Your Members’ Health with Optum HouseCalls
- Delivering on the Promise of Fertility Care [Case Study]
- HouseCalls Nurse Shares Her Story of In-Home Care [Video]
- 6 Thoughts: Shipping Refrigerated Medications
- Top Questions for Life Sciences Stakeholders
- Improve Fertility Treatment Efficiencies & Outcomes
- The Unifying Power of Integrated Data
- Challenges and Considerations When Financing Your EHR
- HouseCalls: Reach Members Where They Are [Guide]
- Research Findings to Support Youth Mental Health Needs
- Support for Substance Use Disorders [White Paper]
- Understanding Students’ Mental Health Needs [Report]
- Care Pathways Study: Early Intervention of Mental Health Care
- Wellbeing in the Workplace Study
- Emotional Wellbeing Solutions Offer Support for Everyday Life
- Optum, FDA Collaborate on Vaccine and Biologic Research
- Improving Maternal and Infant Health Equity
- Address Health Equity Barriers in Cancer Care [E-book]
- Evidence in Action Newsletter for Life Sciences Leaders
- Revolutionizing Cardiology at Boulder Community Health
- What to Know About Managing Rising Transplant Costs
- 2025 CMS Advance Notice: Viewpoints
- Health Insurer Improves Underwriting Results
- Increasing At-Home Dialysis for ESRD Patients
- How to Achieve More Inclusive MSK Care
- Provider Services Module for NASPO ValuePoint
- More Inclusive MSK Care: How Can Employers Help
- Moving Toward Preemptive Kidney Transplants
- Senior Brain Health and Social Interaction
- Cancer Costs Are Rising — Are You Ready?
- Women’s Health: Susan’s Story
- Holistic Fitness Programs for Seniors
- Why Use the Cloud for Medical Imaging
- Payer-Provider Collaboration in ESRD Care
- Intelligent Workflow Case Study
- How Payers Can Address Family-Building Inequities
- Spotlight: Fitness Needs Across Generations
- Emotional Wellbeing Solutions for Healthcare Workers
- Addressing Social Determinants of Health
- Personalized Support for Members with Autism
- Fight the Opioid Epidemic with Medication Interventions
- Investing in Employees’ Financial Wellbeing
- Re-Examining Radiology
- Reduce Risk and Capture Lost Revenue
- Guidance for Health Plans Along the Fertility Journey
- Strategic Planning for Imaging in the Cloud
- Maximize Digital Mammography Reading Efficiency
- Improve Your Radiology Performance
- How Health Data Can Improve MSK Care for Members
- How to Implement Patient-Centered Oncology Care
- Explore Our AI-Enabled Radiology Portfolio
- Kidney Care Breakthroughs: What Payers Should Know
- Change Healthcare Workflow Intelligence Video
- AI-Powered Study Prioritization
- How AI Is Delivering Efficiencies for Radiologists
- Mitigating Maternal Care Deserts
- 5 Ways Shift-of-Site Care Is a Win for All Women
- Access Point-of-Care Ultrasound Imaging Data
- Success Stories in Connected Care
- Structured Cardiovascular Reporting [Case Study]
- A Single Database Cardiology Platform That Drives Efficient Workflow
- Future-Ready Claims Review: Automation Isn’t Enough
- How Employers Can Make Better Benefits Decisions
- Understanding the Benefits of Single-Database Cardiology
- Addressing the High Cost of Musculoskeletal Care Deferral
- Elevating Employee Engagement [Case Study]
- Inventory Management Solutions Made Simple
- Five Ways to Improve Your Cardiovascular Workflow
- Wellbeing Shifts with Meaningful Impact
- When Healthcare Works Better for Everyone
- Imaging, Data Reporting and the Cardiology User Experience
- How to Transform Imaging with Behavioral Science
- Advancing Maternal Health: A Collaborative Approach
- Making Cardiovascular Data Work for the Future
- Designing Cardiac Training Programs Through Innovation
- Optimize Member Engagement Through Collaboration
- Support Your Workforce with Emotional Wellbeing Solutions
- Targeted Care and Lower Cost: How One State Achieved Both
- How Cardiology IT Solutions Can Solve Workflow Issues
- The Benefits of Cardiovascular Structured Reporting
- Behavioral Science to Inform Hemodynamics Product Design
- How RPA Is Improving Healthcare
- Find Immediate ROI with Cloud-Native Enterprise Imaging
- The Role of AI in Enterprise Imaging
- The AI Technology Transforming Imaging
- Four Ways to Strengthen Your Practice
- Change Healthcare Stratus Imaging Share Saves
- The Rising Trend of Hospital-Employed Anesthesiologists
- Cloud-Based Upgrades
- Increase Physician Practice Revenue
- MIPS Program: Recommendations for Physicians
- Navigating Growth in the Healthcare Industry
- Assessing the No Surprises Act
- Optimizing Physician Reimbursement
- The 3 Pillars of Physician Revenue Cycle Management
- Security Capabilities of Cloud-Native Imaging
- Breast Density: Research for Radiologists
- Protecting Taxpayer Dollars [Case Studies]
- Move Your Enterprise Imaging to the Cloud
- Support State Medicaid Goals for Members
- Cyberthreat Webinar
- Migrate Your Enterprise Imaging to the Cloud
- Costs for Unrecognized Kidney Disease
- Artificial Intelligence: A Radiologist’s Replacement or Partner?
- Behavioral Healthcare Made Better
- The Costs and Benefits of Cloud-Based Imaging
- Helping Members Achieve Their Goals
- Supporting Employee Wellbeing After a Loss
- Working Together to Help End the Opioid Epidemic
- Are Your Employees Checked Out or Mentally Present?
- Supporting the Unique Needs of Firefighters
- Addressing Burnout with Cloud PACS Solutions
- Doubling Down on the Cloud
- Southwest Medical Mobile Clinic Brings Care to the Community
- Monitoring COVID-19 Vaccine Safety
- White Paper: New Dimensions in Life Sciences Research
- Creating Better Understanding of Insomnia with Real-World Data
- Generating New Data: Voice-to-Claim Research Methodology
- Is the Treatment Safe for Pregnancy and Infants?
- Outcome-Based Contracting for Life Sciences Manufacturers
- Improve Healthcare Laboratory Processes
- White Paper: 4 Myths on Carving Out Specialty Pharmacy
- Real-Time Prescription Benefits Save Time and Improve Safety
- Closing the Gaps in Pain Management [White Paper]
- Explore Five Priorities to Improve Financial Performance
- Establish Renewed Priority on Revenue Loss
- Boulder Community Health Partners for Employee Success
- Why CAPs Impact Health Plan Stars
- Reimagining Senior Care [White Paper]
- HouseCalls: Fewer Emergency Visits, Hospital Stays
- The Impact of In-Home Health Assessments [Guide]
- Health Equity and Women’s Health
- Reduce Your Claim Denials with These 5 Tips
- Improving UR Effectiveness with Case Advisor
- Improving Performance at Excel Medical Center
- Electronic Health Records (EHR): Implement and Operate
- Engage Providers to Impact Member Outcomes [Infographic]
- Improve Medicaid Risk Adjustment Accuracy
- How to Reduce Administrative Waste in Health Systems
- How AI Accelerates Workflows and Patient Cancer Care
- 5 Provider Strategies to Help Improve Your Margins
- Modernize Your Revenue Cycle Workforce
- 6 Key Considerations for Provider Management Modernization
- 4 Steps to Optimizing Value-Based Care
- Risk Adjustment and Star Ratings Success
- Reduce Avoidable Medicaid Claims Denials
- Anesthesia Practice Improves Profitability with RCM Services
- Outsourcing Medical Billing
- Think Differently: Strategies for Incremental Modernization
- Call Centers & AI: Game Changer for State Government
- M&O Innovations: Claims Automated Rules Engine
- Connected Care Models Webinar
- Connected Care Models Webinar | Optum
- Improving Outreach Lab Performance
- How Optum Billing Systems Boost Revenue
- Helping an Emergency Services Practice Streamline Accounting
- The Fight for Techquity
- Emergency Department Performance Metrics
- Digital Health Engagement Guide
- Optum RCM Services Help Pathology Practice Scale and Grow
- 2024 Healthcare Trends Report
- Provider Report Cards for Emergency Medicine Groups
- Care Delivery Innovation
- Optum RCM Services Help Pathology Group Increase Collections
- Building a Youth-Centered Mental Health Care System
- Building a Health Equity Strategy
- Price Transparency: Giving Patients a Clear Look at Their Care
- “No Regret” IT Investments for Health Systems
- Enhance Patient Satisfaction with Easier Medicaid Enrollment
- Modernizing the Medicaid Experience
- The Value of DEX Z-Codes in the Commercial Space
- The Benefits of a Cloud-Native Environment
- Can Automation Cure Healthcare Workforce Challenges?
- Can Innovation Help the Health Care Workforce Crisis?
- Automation and Workforce Strategies in Healthcare
- Reducing Avoidable Medicaid Claims Denials
- Path To Techquity
- Helping States Serve Members Holistically
- What If Pragmatic Clinical Trials Were More Practical?
- Best Practices in Modernizing Your State’s Legacy System
- Entity Uses HealthFocus to Streamline Services [Case Study]
- Preserving Talent & Enabling Career Growth for Healthcare Providers
- Leading Perspectives and Market Trends for Health Plans
- Hearts Behind the Work: Meet Our People
- Healthier Outcomes for Moms and Babies Through Data
- Breast Cancer Awareness Month
- Help Members Access Behavioral Healthcare Resources and Support
- Autoimmune, Oncology, Diabetes and Obesity Rule Drug Spending
- Specialty Drug Management and Patient Follow-up
- Paperless Pharmacy Communications
- PBM Regulations to Watch: Summer 2024
- Avoid Surprises in Pharmacy Spend
- Drug Pipeline Insights Report Spring 2024
- Preparing Your Plan for the GLP-1 Era
- Preparing Your Plan for the GLP-1 Era
- Optum Rx Specialty Standards Program
- Building the PBM of the Future: A Guide
- Advancing Access to Whole Genome Sequencing
- Innovating Risk Adjustment Strategies
- Debunking revenue cycle myths: The path to financial health
- SDOH Solutions: Transforming Health Care for All
- White Paper: Automate to Address Staff Pinch
- Utilizing Patient Access Contact Center Services
- Diagnosis and Care Recommendations for Rare Congenital Anomaly
- Navigating the Two-Midnight Rule in the Medicare Advantage World Webinar
- Watch webinar
- Bring Your Wellness Strategy to Life for Employees
- Build a Culture of Health in the APAC Region
- Drive Wellbeing Programme Utilisation for Employees
- NLP Technology: Unlock Clinical Insights for Critical Research
- How Health Systems Are Navigating Razor-Thin Margins
- Site of Care A Longitudinal Review [Webinar]
- How to Ease the Emotional Toll of Caregiving for Members
- Clinicogenomic Data: Challenges and Opportunities
- Digital Health Technology Challenges & Opportunities [Video]
- Partnering to Close Gaps in Maternal Health
- Impacting Provider Engagement
- Front-end RCM strategy
- Improve Employee Well-Being Engagement and Use
- 2024 10 Hurdles e-book | Optum
- 2024 10 Hurdles e-book
- Employer Insights for Health and Well-Being
- Establishing Trust to Improve Value-Based Care Outcomes
- Fecal Transplant to Treat Recurrent Urinary Tract Infection
- Transforming Front-End RCM to Minimize Claim Errors
- Guide to 5 Types of Vendors and Partners
- Revenue Cycle Innovation to Decrease Uncompensated Care
- How CAPs Directly Impact Your Stars Performance
- The New Digital Landscape: Meeting Consumer Expectations
- Rethinking the Healthcare Payment Process
- Trends for Health Plan Quality Performance
- SDOH Solutions: Improving Population Health Outcomes
- Best Practices of Utilization Review [Webinar]
- Top 5 Pharmacy Benefits Stories in 2024
- Transforming CDI and Coding with Advanced Analytics
- Streamline Medicaid Eligibility and Enrollment Processes
- Coding Audits: Why & How to Do Them
- Your Medicaid & Human Services Contact Center: What's Next?
- Evolving with Age: How Leaders Can Enhance the Senior Healthcare Experience
- Consumer-Centric Healthcare Research Report
- Why Partnerships are Key to Tackling Maternal Health in D.C.
- How Transparency Helps Medicaid Providers Serve Patients
- How to Push Back on 3 Key Pharmacy Headwinds
- Star Ratings Are Important to Medicare Plans
- 4 Shifts Shaping the Future of Oncology Care and Treatment
- Access to Mental Health Care Within 48 Hours
- Automating the Prior Authorization Process
- Meet Consumer Expectations, Address Provider Frustrations
- Survey: How Healthcare Costs Can Influence the Patient Journey
- Viewpoints on the 2025 CMS Final Notice
- The Health Equity Alignment Solution (HEALS)
- Carving the Path to Value-Based Care
- Addressing Loneliness Epidemic & Cognitive Decline in Seniors
- InterQual AutoReview: A Fact Sheet
- Does Your Patient Engagement Platform Check All the Boxes?
- Automation Strategies for Empowering Staff and Patients [Webinar]
- Automation Strategies for Empowering Staff and Patients [Webinar]
- Aging Workforce and the Impact on Drug Spend
- 5 Questions on Health Equity
- GLP-1s: Navigating High Costs & Coverage Options
- Biosimilar Interchangeability: Practical Steps to Improve Uptake
- The State of Pharmacy Regulation: An Interview
- The Value of Clinical Notes: Beyond the Structured Data Field
- Achieving Equitable Care: The Shift to Race-Neutral Equations
- Challenges of evaluation for patients with acute coronary syndrome
- How to Make Home Dialysis the Industry Standard
- Reexamine the Effect of the Inflation Reduction Act
- Key New Drugs Help Close Out 2024
- Health Loyalty & Rewards Programs: What Consumers Want
- How CMS Quality Measure Rules in 2024 Will Impact States
- White Paper: Rising Expectations Among Healthcare Consumers
- System Modernization for Health Plans [E-book]
- Our New Patient Access and Engagement Platform [Webinar]
- Webinar
- Automating Success: Revenue Cycle Transformation
- PBM Regulations to Watch: Fall 2024
- Everest Group Guide to Selecting RCM Services
- Improving Hospital Quality & Utilization [Case Study]
- Design an Exceptional Physician Review Strategy
- New Options to Treat Schizophrenia, COPD [Report]
- How to Effectively Manage Organ Transplant Costs
- An Employee Benefits Strategy that Balances Cost and Care
- Packaging Your Employee Benefits Experience
- Exploring the Health Savings Pathways Series
- How Hub and Advocacy Solutions Work Together for Employers
- Revolutionizing Specialty Medication Management [E-book]
- 3 Ways Holistic MSK Care Improves All Avenues of Care
- Reimagining Fraud Prevention
- Drive Efficiency and Performance with Middle RCM Tech
- Enterprise Transformation with Optum Advisory
- Developing Evidence-Based Tools for Accessible and Quality care
- Workforce Wellness Programs Must Reward More Than Tasks
- Benefit communication strategy use case: Engage employees with personalization | Optum
- How an Optum Care Coordinator Works [Video]
- When Chronic Conditions and Behavioral Health Collide
- Advancing DME Benefits Management with DME Navigator
- Transform Underwriting with Cutting Edge Technology
- How Payers Can Improve Maternal Care in the 4th Trimester
- Building a Better Oncology Managed Care Program
- Supporting Women Beyond the Reproductive Years
- Optum Rx Drug Pipeline Insights Report Winter 2025
- A Forward Approach to Medical Coding Accuracy
- How to Build a Mobile Crisis Team
- Improve Provider Engagement with Optum Mobile Query
- Improve Provider Engagement with Optum Mobile Query
- Safeguard the Mental Health of Content Moderators
- The Future of Quality Reporting
- The Importance of Workforce Mental Health Maintenance
- Revenue Cycle Ripple Effect on Patient Experience | Optum
- Increasing Behavioral Health Patient Access with Self-Scheduling
- Continuous Insurance Coverage Discovery | Optum | E-book
- Discover 8 capabilities to power your EHR
- Pharmacy Care Insights | Optum Business
- Which Health Care Growth Strategy is Right For You?
- Strategies to Promote Maternal Health Equity
- Integrating Risk and Quality Programs for Health Plans
- Viewpoints on the 2026 CMS Advance Notice
- Optum Recognized as RCM Leader Report
- New Pharmacy Benefit Solutions to Help Bend the Cost Curve
- Supporting Members for Better Mental Health [Video]
- Reduce Polypharmacy Risks in Nursing Homes
- Advancing Infection Prevention in Senior Communities [E-book]
- How Senior Care Facilities Can Elevate Dementia Care
- Reduce Length of Stay, Enhance Care Quality and Resource Efficiency
- Download the HCC Tearsheet 2025: Quick Coding Guide
- Improving Payment Integrity in Healthcare
- Are Your Pharmacy Benefits Working Hard Enough? [E-Book]
- Weight Loss Medications: What Real-World Data Can Reveal
- Helping Members Find In-the-Moment Support [Video]
- Objective Frailty Criteria for Complex Patient Reviews
- Optimize Employee Benefits with Healthcare Analytics
- Women’s Health is Far More than Reproductive Care [E-book]
- Focus on Provider Satisfaction to Expand Mental Health Access
- Supporting Family Mental Health
- Health Plan Quality Ratings Dashboard
- Digital Integration and the Path to Interoperability
- The Foundational Forces Affecting Pharma [E-book]
- Social Determinants of Health in Urban America
- Bridge the payment gap between payers and providers
- 5 Questions You Should Answer with Real-World Evidence
- Addiction Treatment with The ASAM Criteria® Fourth Edition
- Addiction Treatment with The ASAM Criteria® Fourth Edition [Webinar]
- A Quarter-Century of Pharmacy Benefit Changes [E-Book]
- RCM Priorities for 2025
- Supporting Service Line Growth & Development with Data | Optum Business
- Webinar | Optum Business
- How Payers Can Prepare for Rise of Cellular Therapy Patients
- Transform Pharmacy Benefits with End-to-End Transparency
- How Real-World Evidence Can Inform Pharma Strategies in 2025
- PBM Regulations to Watch: Spring 2025
- Small Price Hikes Make for Big Drug Prices
- Understanding the transition to cloud-native imaging | Optum
- Digital MSK Tools: 5 Important Features
- Tailoring Medicare Plans
- Delivering a deeper connection to infusion care | Optum
- Specialty vs. Retail Pharmacy: What's the Difference?
- Quick and Safe Digital Specialty Pharmacy Service [Video]
- Holistic Care Model Gives New Hope for Neurological Conditions
- White Paper: Outlook on Oncology in 2024
- Delivering Specialized Pharmacy Care
- How Our Medication Packaging Helps the Planet
- Sustainable Future for Alternate-Site Infusion Pharmacy Care
- Addressing Extreme Cost & Lack of Catheter Lock Options
- Tech and VBC Models: Enhancing Payer-Provider Partnerships
- Clinical value analysis process in a growing surgical market
- Confirmation
- Unblocking the Digital Access Journey
- The Challenge of Managing Rising Neonatal Costs
- Can a Holistic Approach Help with UM Challenges?
- How Patient-First Care Helps Women With Cancer
- Interoperability to enhance prospective risk management
- Transition to cloud-native imaging case study
- The state of value-based care in 2025: Growth and challenges
- New Drugs for Myasthenia Gravis & Hereditary Angioedema
- The Big Picture on Pharmacy: An Interview
- Driving Efficiency and Accuracy Across the Middle Revenue Cycle
- Driving Efficiency and Accuracy Across the Middle Revenue Cycle
- Best Practices for Efficient Medical Record Retrieval
- Viewpoints on the 2026 CMS Final Rate Announcement
- Extracting Value-Based Care Insights from Claims Data
- Enhancing Contact Center Efficiency and Customer Experience
- How Organizations Can Support Neurodiversity in the Workplace
- Maximizing CareSelect Imaging for Value-Based Care
- Maximizing CareSelect Imaging for Value-Based Care
- AI Advancements Bridge the Gap to Dual Eligibility Enrollment
- High Price We Pay When Seniors Lack Access to Health Care
- The Role of Imaging Decision Support in Value-Based Care
- The Secret to Success in Risk Adjustment and Value-Based Care Programs
- How Medicare Advantage Leaders Can Support D-SNP Market
- What to Expect From Pharmaceutical Tariffs
- How Do Pharmacy Benefit Managers Work? [Video]
- 3 Key Steps to Building an Effective Annual Wellness Visit Program
- Empowering growth through Working Capital
- Transforming Care Through Payer-Provider Collaboration
- Employer Health Solutions | Optum Business
- Healthcare Technology Optum Channel Partner Solutions
- Brokers and Consultants | Optum Business
- Healthcare Provider Solutions | Optum Business
- A Trusted Partner of State Governments | Optum Business
- Industry Associations for State Agencies | Optum Business
- Devoted to Improving Lives Across the Nation | Optum Business
- About Optum Serve - A Federal Health Services Business
- Federal Government Contract Vehicles | Optum Business
- NITAAC Chief Information Officer | Optum Business
- Careers at Optum Serve Consulting | Optum Business
- Certifications & Industry Partnerships | Optum Business
- Small Business Partners in the Federal Market | Optum Business
- Optum Serve Recent News & Upcoming Events
- Veteran Careers at Optum: Explore Opportunities | Optum Business
- Research Study: Caring for Veterans and Military Families
- Payer Solutions in Healthcare | Optum Business
- Optum | Always Innovating
- Healthcare Consulting Services | Optum Business
- Optum Advisory: Healthcare Consulting Services
- Analytics Consulting | Optum Business
- Risk Management & Analytics Consulting | Optum Business
- Government Programs - Advisory Services | Optum Business
- Group Risk Analytics: Predict Future Risk | Optum Business
- StepWise and Underwriting | Optum Business
- Management Consulting | Optum Business
- Strategy & Growth: Partnering with Healthcare Organizations
- Technology Consulting | Optum Business
- Health Policy Consulting | Optum Business
- Health Policy Capabilities | Optum Business
- Providing Data-Driven Actionable Insights to the Life Sciences Industry
- Improving Healthcare Access | Optum Business
- Healthcare Access for State HHS Agencies | Optum Business
- Optum Integrated Eligibility Services | Optum Business
- Optum Maintenance and Operations Services | Optum Business
- State-Based Exchanges | Optum Business
- Healthier Care for Your Clients | Optum Business
- Help Your Clients Become Optum Arizona Patients
- Help Your Clients Become Optum Connecticut Patients
- Optum and WellMed Agent Resources in Florida
- Help Your Clients Become Optum Utah Patients
- Sign Up for Our Agent Newsletter | Optum Business
- Home & Community Care | Optum Business
- HouseCalls: In-Home & Virtual Visit Program | Optum Business
- naviHealth Post-Acute Care Solutions | Optum Business
- Senior Living Community Program | Optum Business
- Skilled Nursing Facility Program | Optum Business
- Full Population Management Solution | Optum Business
- Digital Patient Access and Engagement Solutions
- Patient Acquisition and Online Scheduling Solutions
- Patient Intake, Engagement and Retention Solutions
- Provider Growth and Analytics | Optum Business
- Optum Market Advantage | Optum Business
- Patient Acquisition Services: Leverage Data to Drive Growth
- Health Services for Military and Veterans | Optum Business
- Public Health, Preparedness, Response & Recovery Services
- Assured Access: Rapid Resource Deployment in Emergencies
- Medical Mobile Units | Optum Business
- Federal Health Programs by Agency | Optum Business
- VBA Medical Disability Examinations | Optum Business
- Community Care Services for Veterans | Optum Business
- Global Medical Services | Optum Business
- Data & Analytics Solutions | Optum Business
- Benefits Analytic Manager for Employers | Optum Business
- Data & Analytics Solutions for State Governments
- Healthcare Performance Analytics | Optum Business
- Rapid Insights as a Service | Optum Business
- Program Integrity to Manage Fraud, Waste and Abuse | Optum Business
- State Data Hub: Healthcare Data Management | Optum Business
- State & Federal Reporting Analytics Module | Optum Business
- Policy, Research and Consulting | Optum Business
- Life Sciences Solutions: Turning Evidence into Action | Optum Business
- Enhance Clinical Trial Design and Performance | Optum Business
- Optimize Feasibility & Protocol Development | Optum Business
- Reduce the Burden on Clinical Trial Sites | Optum Business
- Streamline Data Collection in Clinical Trials | Optum Business
- Clinicogenomics Data Advances Life Sciences Research | Optum Business
- Empower Commercial, Brand & Access Teams | Optum Business
- Design & Pilot Engagement Programs for Patients
- Partner with Our Epidemiology Consultants | Optum Business
- Dynamic Assessment of Pregnancies & Infants (DAPI) | Optum Business
- HEOR: Strengthen Your Value Story | Optum Business
- HEOR for Cardiovascular Disease | Optum Business
- HEOR Cardiovascular Publications | Optum Business
- HEOR for Central Nervous System | Optum Business
- HEOR for Diabetes & Endocrine Diseases | Optum Business
- HEOR for Infectious Diseases | Optum Business
- HEOR for Oncology & Immunology | Optum Business
- Voice-to-Claim Research Methodology | Optum Business
- HEOR for Rare Disease | Optum Business
- HEOR for Respiratory Diseases | Optum Business
- Unlock Data Insights with Exploratory Analysis | Optum Business
- Real-World Data for Life Sciences Research | Optum Business
- Claims Data to Help Clarify Market Dynamics | Optum Business
- Electronic Health Records (EHR) Data | Optum Business
- Market Clarity: Linked EHR and Claims Data | Optum Business
- Enriched Clinical Data for Quality Research | Optum Business
- Value-Based Contracts to Engage Payers | Optum Business
- Optum Enlighten: Gain a Truer Picture of Disease Prevalence
- Infectious Disease Surveillance: Plan with Confidence
- Optum Evidence Engine
- Pharmacy Business Intelligence Solutions | Optum Business
- Exchange Dx™ | Optum Business
- Explore Dx® | Optum Business
- Provider Data Collaborative: A Virtual Data-Sharing Community
- Data and Analytics for Healthcare Providers | Optum Business
- Surgical Profitability Compass | Optum Business
- Symmetry Suite: Measure Value with Standard Units of Analysis
- Enterprise Business Intelligence Solutions | Optum Business
- Physician Review for Workflow Management | Optum Business
- Hospital Quality & Utilization Optimization | Optum Business
- Data & Information Technology Consulting for Federal Agencies
- Program Integrity Services | Optum Business
- Health Benefits Solutions | Optum Business
- Behavioral Health & Emotional Wellbeing Solutions | Optum Business
- Behavioral Health Solutions for Employers | Optum Business
- Substance Use Disorders Solutions | Optum Business
- Behavioral Health Care Solutions for Health Plans
- Behavioral Health Solutions for State Governments
- Behavioral Health Programs for the Justice-Involved
- Integrated Solutions for I/DD Populations | Optum Business
- Peer Support Services for Behavioral Health | Optum Business
- Behavioral Health Solutions for Military & Veterans
- Complex Care Management | Optum Business
- NurseLine Services: Patient Education & Support
- Bariatric Resource Services | Optum Business
- Focused Claims Review for Billing Accuracy | Optum Business
- Musculoskeletal Solutions: Manage Utilization & Spend
- Oncology Care Management Solutions | Optum Business
- Optum Oncology Pathways: Enhance Quality in Cancer Care
- Transplant Solutions: Reduce Your Medical Expenses
- Managed Transplant Program for Health Plans | Optum Business
- Transplant Resource Services | Optum Business
- Managed Transplant Program for Employers | Optum Business
- Specialty Management Solutions | Optum Business
- Transform Specialty Drug Management with Specialty Fusion
- Specialty Pharma Solutions | Optum Business
- Prevention & Well-Being | Optum Business
- Biometric Screenings & Vaccinations | Optum Business
- Optum Hub: A Curated Network of Trusted Healthcare Vendors
- One Pass Select: Fitness & Well-Being Program
- One Pass for Medicaid: Making Fitness & Nutrition Accessible
- Women’s Health Solutions | Optum Business
- Fertility Solutions & Support | Optum Business
- Maternity Support Program for Employers | Optum Business
- Neonatal & NICU Support Programs | Optum Business
- OB Homecare Programs for Health Plans | Optum Business
- OB Homecare Solutions for Providers | Optum Business
- One Pass for Medicare: Helping Seniors Make Healthier Choices
- Optum Engage: A Health Rewards & Engagement Platform
- Workplace Well-Being: Fitness & Wellness Programs
- Corporate Fitness Center Management | Optum Business
- Global Employee Assistance Program (EAP) Solutions
- Optum Guide: Health Advocacy Solutions for Employers
- Healthcare Operations & Technology | Optum Business
- Evidence-Based Clinical Decision Support Solutions
- EHR Clinical Decision Support Tools | CareSelect®
- Medical Imaging Clinical Decision Support | Optum Business
- Cloud-Based Imaging Decision Support | Optum Business
- Lab Test Utilization Management | Clinical Decision Support
- CareSelect® Risk Assessor for Breast Cancer Risk Assessment
- Optum Case Advisor | Optum Business
- Clinical Assistant
- Evidence-Based Criteria & Guidelines | InterQual®
- InterQual® Alliance Partners | Optum Business
- Third-Party Industry Content Navigator | InterQual®
- Automated Medical Necessity Reviews | Optum Business
- InterQual Criteria | Optum Business
- InterQual® Technology Solutions | Optum Business
- InterQual® Optimization Solutions | Optum Business
- InterQual® Coordinated Care | Optum Business
- Prescription Adherence and Clinical Management | Optum
- Integrated Utilization Management | Optum Business
- Case Intelligence
- Clinical Operations | Optum Business
- Ancillary Benefits Management | Optum Business
- DME Navigator: Get the Right Medical Equipment
- Lab Benefit Management
- Genomics Payment Manager
- Hospital Case Management Optimization | Optum Business
- Hospital Case Management Managed Service | Optum Business
- Information Technology (IT) Performance in Healthcare
- Patient Help Line Support for Healthcare Providers
- Practice Extend Program | Optum Business
- Practice Extend for Providers | Optum Business
- Medicare Shared Savings Program | Optum
- System Evolve
- Enterprise Imaging | Optum Business
- Change Healthcare Cardiology™ Solutions | Optum Business
- Change Healthcare Cardiology™ Analytics | Optum Business
- Change Healthcare Cardiology™ PACS | Optum Business
- Change Healthcare Cardiology Cath | Optum Business
- Change Healthcare Cardiology Charge Manager™
- Change Healthcare Cardiology ECG Management™
- Change Healthcare Cardiology Echo™ | Optum Business
- Change Healthcare Cardiology EP Solutions™ | Optum Business
- Change Healthcare Cardiology Hemodynamics™
- Change Healthcare Cardiology Nuclear Medicine Advanced Visualization™
- Cloud-Based Inventory Management | Optum Business
- Enterprise Imaging Contract Staffing | Optum Business
- Change Healthcare Radiology Solutions | Optum Business
- Change Healthcare Enterprise Viewer™ | Optum Business
- Change Healthcare Imaging Actionable Findings
- Change Healthcare Imaging Fellow™ | Optum Business
- Change Healthcare Image Repository™ | Optum Business
- Change Healthcare Mammography Plus™ | Optum Business
- Change Healthcare Radiology Solutions™ | Optum Business
- Change Healthcare Workflow Intelligence™ | Optum Business
- Stratus Imaging | Optum Business
- Change Healthcare Stratus Imaging Analytics | Optum Business
- Change Healthcare Stratus Imaging Archive | Optum Business
- Change Healthcare Stratus Imaging Discover | Optum Business
- Stratus Flex for Radiology | Optum Business
- Change Healthcare Stratus Imaging Share | Optum Business
- Change Healthcare Stratus Imaging PACS | Optum Business
- Change Healthcare Stratus Imaging Viewer | Optum Business
- Network Connectivity | Optum Business
- Clinical Exchange Solutions | Optum Business
- Enhance Care with Clinical Exchange ePrescribe | Optum Business
- Clinical Exchange Orders and Results | Optum Business
- Dental Network Solutions | Optum Business
- Dental Benefits Advisor | Optum Business
- Dental Converge | Optum Business
- Medical Network Solutions | Claims Clearinghouse
- EDI Network | Optum Business
- Hosted Payer Services | Optum Business
- Payer Connectivity Services | Optum Business
- Portals | Optum Business
- Pharmacy Network Solutions | Optum Business
- Optimal Pharmacy Network Strategy | Optum Business
- Rx Assist | Optum Business
- Rx CardFinder™ Services | Optum Business
- Rx Connect™ | Optum Business
- Rx Cost Savings Advocate | Optum Business
- Rx Edit | Optum Business
- Epic Payer Platform Managed Services | Optum Business
- Pharmacy Technology Solutions | Optum Business
- Pharmacy Management Software Solutions | Optum Business
- Converge Rx™ | Optum Business
- Enterprise Pharmacy System™ | Optum Business
- Program Operations for State Governments | Optum Business
- One Assist: Omnichannel Contact Center Solution
- Preadjudication Suite for State Governments | Optum Business
- Provider Management Services for Medicaid Agencies
- Healthcare Revenue Cycle Management Solutions | Optum Business
- Ambulatory Revenue Cycle Management Services
- Anesthesiology RCM Services | Optum Business
- Laboratory RCM Services | Optum Business
- RCM Services for Emergency Medicine Practices
- Revenue Cycle Management for EMS Agencies
- Multispecialty RCM Services | Optum Business
- Pathology RCM Services | Optum Business
- Radiology RCM Services | Optum Business
- Telehealth RCM Services | Optum Business
- Ambulatory Revenue Cycle Technology | Optum Business
- Revenue Performance Advisor | Optum Business
- SmartPay Plus: Payment Solution | Optum Business
- Patient Access Services for Revenue Cycle Management
- Connected Authorization Services | Optum Business
- Coverage Insight: Insurance Verification Software
- Eligibility and Enrollment Services | Optum Business
- Patient Access Contact Center Services | Optum Business
- Patient Financial Clearance: Insurance Verification Solution
- Optum Patient Payments | Optum Business
- Pharmacy Revenue Cycle Billing Solutions | Optum Business
- Absolute AR® | Optum Business
- MedRx™ | Optum Business
- Medical Claims & Reimbursement Management Solutions
- A/R Recovery and Denial Management | Optum Business
- Medical Claim Software for Reimbursement Management
- Business Office Performance Services | Optum Business
- Claims Manager | Optum Business
- Prevent Claim Denials with Provider Communication Gateway | Optum Business
- Revenue Integrity Solutions | Optum Business
- Clinical Language Intelligence (CLI) | Optum Business
- Health Information Management Outsourcing | Optum Business
- Medical Coding Services to Improve Clinical Documentation | Optum Business
- Enterprise Computer Assisted Coding (CAC) & CDI 3D
- Professional Computer Assisted Coding (CAC) | Optum Business
- LYNX Outpatient Charge Capture | Optum Business
- Medical Coding Books, Software & Data | Optum Business
- Optum Integrity One
- Acuity Revenue Cycle Analytics | Optum Business
- Risk Adjustment, Quality & Engagement | Optum Business
- Prospective Solutions for Health Plans | Optum Business
- We Partner with Doctors to Support Patient Outcomes
- Risk Identification and Capture | Optum Business
- Medicaid Risk Adjustment | Optum Business
- Healthcare Member Engagement Solutions | Optum Business
- Social Care Assistance | Optum Business
- Optum | Dual Enrollment Advocate and Recert Complete
- Health Engagement Platform | Optum Business
- Quality Solutions for Health Plans | Optum Business
- Optum Medical Record Retrieval | Optum Business
- Retrospective Risk Adjustment - Health Plan Solutions
- Audit Services | Optum Business
- Retrieval Services | Optum Business
- Submission Services for Health Plans | Optum Business
- Risk Analytics
- Market Performance Partnership | Optum Business
- Payment Integrity - Health Plan Solutions | Optum Business
- Claim Pricing – Health Plan Solutions | Optum Business
- Claims Edit System - Health Plan Solutions | Optum Business
- Comprehensive Denial Prevention – Health Plan Solutions
- Emergency Department Claim (EDC) Analyzer | Optum Business
- Claim Review – Health Plan Solutions | Optum Business
- Data Mining – Health Plan Solutions | Optum Business
- Coding Advisor – Health Plan Solutions | Optum Business
- Coordination of Benefits (COB) – Health Plan Solutions | Optum Business
- Credit Balance – Health Plan Solutions | Optum Business
- Pharmacy Services: Increase Medication Adherence & Outcomes
- Home Delivery Pharmacy: Simplify Medicine Delivery | Optum Business
- Home Delivery Pharmacy for Payers | Optum Business
- Home Delivery Pharmacy for Providers | Optum Business
- Electronic Prescribing (eRx) to Optum Home Delivery
- PreCheck MyScript: Real-Time Benefits Check Tool Data | Optum Business
- Infusion Pharmacy for Providers | Optum Business
- Specialty Pharmacy: Support for Specialty Medications | Optum Business
- Specialty Pharmacy for Providers | Optum Business
- Gastroenterology Center of Excellence | Optum Business
- Immunology Center of Excellence | Optum Business
- Neurology Center of Excellence | Optum Business
- Oncology Center of Excellence | Optum Business
- Specialty and Infusion Drug List | Optum Business
- Specialty Provider Portal | Optum Business
- Pharmacy Appeals to Help Patients Get Medication Coverage | Optum Business
- Cardiopulmonary Center of Excellence | Optum Business
- Pharmacy support for hospitals and healthcare systems | Optum Business
- Pharmacy Care Support for Payers | Optum Business
- What a Specialty Pharmacy Can Do for Pharma Manufacturers
- Specialty Pharmacy Community Residency | Optum Business
- Electronic Prior Authorizations for Prescribers | Optum Business
- Pharmacy Benefit Management (PBM) | Optum Business
- Lowering Pharmacy Benefit Costs | Optum Rx Business
- Weight Engage: An Innovative Weight Management Solution
- Driving Pharmacy Innovations for Today and Tomorrow
- Making Pharmacy Benefits Clear | Optum Rx Business
- Regulatory Updates | Optum Rx Business
- Hospice Pharmacy Solutions | Optum Business
- Hospice Pharmacy Analytics Tools | Optum Business
- Hospice Pharmacy Clinical Programs | Optum Business
- Hospice Pharmacy Educational Resources | Optum Business
- HospiBooks: Hospice Care Books | Optum Business
- Hospice Technology Solutions to Improve Patient Care
- Pharmacy Network for Hospice Care | Optum Business
- Helping Members Better Manage Pharmacy Care | Optum Business
- Using Data to Improve Health Equity for Pharmacy Members | Optum Business
- Simplifying the PBM Experience | Optum Rx Business
- Optum Rx Benefit Central: Streamline Plan Management
- Driving Appropriate Utilization of Medications | Optum Business
- Controlling Specialty Drug Costs | Optum Business
- Pharmacy Benefit Management for Health Plans | Optum Business
- Financial Solutions | Optum Business
- Health Benefit Accounts for Employers | Optum Business
- Health Savings Accounts for Employers | Optum Business
- Healthy Food Benefits for Employers | Optum Business
- Lifestyle Spending Accounts for Employers | Optum Business
- Stop Loss Insurance for Employers | Optum Business
- COBRA Administration for Employers | Optum Business
- Flexible Spending Accounts for Employers | Optum Business
- Commuter Benefits for Employers | Optum Business
- Health Reimbursement Arrangements for Employers
- Payment Delivery Solutions | Optum Business
- Payment Solutions for Healthcare Payers | Optum Business
- Payment Solutions for Medical Third-Party Administrators
- Payment Platform for Dental Payers | Optum Business
- Payment Solutions for Property & Casualty Claims
- Payment Solutions for Workers’ Compensation Claims
- Payment Solutions for Auto Insurance Claims | Optum Business
- Payments & Lending Solutions for Providers | Optum Business
- Optum Pay: Expedite Claims & Streamline Access to Data
- How to Enroll in Optum Pay | Optum Business
- Working Capital Solutions for Healthcare | Optum Business
- Communications Complete | Optum Business
- Find Your Healthcare Solution | Optum Business